Fwd: Out of Office Response: [Pharm-policy] Re: Pharm-policy digest, Vol 1 #109 - 1 msg

Wed, 12 Jul 2000 09:55:26 +0100

>X-Frontier-To: ymelia@nuffield.ftech.co.uk
>Apparently-To: ymelia@nuffield.ftech.co.uk
>Conversion: Allowed
>Original-Encoded-Information-Types: IA5-Text
>Priority: normal
>Disclose-Recipients: Prohibited
>Alternate-Recipient: Allowed
>Date: 11 Jul 2000 10:31:27 -0700
>From: Anthony Barrueta <Anthony.Barrueta@kp.org>
>To: ymelia <ymelia@nuffieldfoundation.org>
>Subject: Out of Office Response: [Pharm-policy] Re: Pharm-policy digest, Vol 
>1 #109 - 1 msg
>X-MDaemon-Deliver-To: YMelia@nuffield.ftech.co.uk
>
>Anthony Barrueta will be away from Thursday June 29, 2000 to Thursday July 13,
>2000.  Mail is not being forwarded.
>
>
>
>Original Message Text follows:
>----------------------------------------------------------
>
>The full report is on the site.  The title of the report 'Beyond our means'
>etc is in blue, just click on the title in blue and this brings you to the
>page where the report can be downloaded.
>Yvonne
>
>At 12:00 PM 7/11/00 -0400, you wrote:
>>
>>Send Pharm-policy mailing list submissions to
>>	pharm-policy@lists.essential.org
>>
>>To subscribe or unsubscribe via the web, visit
>>	http://lists.essential.org/mailman/listinfo/pharm-policy
>>or, via email, send a message with subject or body 'help' to
>>	pharm-policy-request@lists.essential.org
>>You can reach the person managing the list at
>>	pharm-policy-admin@lists.essential.org
>>
>>When replying, please edit your Subject line so it is more specific than
>>"Re: Contents of Pharm-policy digest..."
>>
>>
>>Today's Topics:
>>
>>  1. Panos Report - "Beyond Our Means?" (Thiru Balasubramaniam)
>>
>>--__--__--
>>
>>Message: 1
>>Date: Tue, 11 Jul 2000 10:30:34 -0400
>>From: Thiru Balasubramaniam <thiru@cptech.org>
>>Organization: Consumer Project on Technology
>>To: Multiple recipients of list IP-HEALTH <ip-health@venice.essential.org>,
>>Multiple recipients of list PHARM-POLICY <pharm-policy@venice.essential.org>
>>Subject: [Pharm-policy] Panos Report - "Beyond Our Means?"
>>
>>Richard Jeffries posted this on healthgap.
>>
>>
>>
>>----------------------------------------------------------------------------
>>----------------------
>>The Panos Report "BEYOND OUR MEANS? The Cost of Treating HIV/AIDS in the
>>Developing World" has been released, there's a whole bunch of info
>>including a summary document on their website. I can't find the whole
>>report, though. Following is a link to the website and a related Reuters
>>story from today.
>>
>>http://www.panos.org.uk/
>>
>>Poor nations pay highest prices for AIDS drugs
>>
>>By Richard Woodman
>>
>>http://www.ama-assn.org/special/hiv/newsline/reuters/07118271.htm
>>
>>LONDON, Jul 11 (Reuters Health) - Poor nations in Africa where the
>>majority of HIV-infected people live sometimes pay higher prices for
>>antiviral drugs than rich western countries, a leading non-governmental
>>organisation said, as the International AIDS Conference began in South
>>Africa this past weekend.
>>
>>The Panos Institute, which campaigns on global development issues,
>>released survey findings showing that the price of Lamivudine (3TC) 150
>>mg ranged from US$340 to $810 in Africa compared with $290 to $524 in
>>Organisation for Economic Cooperation and Development (OECD) countries.
>>
>>It also quoted wide variations in the price of zidovudine (AZT) 100 mg
>>ranging from $86 to $270 in Africa and from $143 to $278 in Europe's
>>OECD countries. The cost of a daily dose of Zalcitabine (ddC) ranged
>>from $0.24 in Brazil to $3.75 in the Ivory Coast and $4.17 in Uganda.
>>
>>In a report entitled "Beyond Our Means?--The cost of treating HIV/AIDS
>>in the developing world," the organisation said, "In May 2000, in
>>response to growing demands, five of the world's largest pharmaceutical
>>companies and UNAIDS announced that prices in the developing world would
>>be drastically
>>reduced.
>>
>>"But the warmth that greeted that announcement soon turned sour, when
>>only one company, Glaxo Wellcome, announced a specific price cut [in
>>relation to Combivir, which would sell through UNAIDS at $2 per day
>>compared with $16 in the US], and the other companies refused to make
>>specific commitments."
>>
>>Panos supporters told a news conference in London that unless companies
>>cut prices there would be increased pressure on governments to ignore
>>patents and introduce compulsory licensing. They pointed to the example
>>of Brazil where intellectual property rights are not always respected
>>with the result
>>that generic drug companies sell the AZT/3TC combination for $1.44 per
>>day compared with $18.78 in the US.
>>
>>They warned that these companies were willing to export drugs at similar
>>low prices to African countries. Another possible solution, they
>>suggested, was that UNAIDS should act as a bulk purchaser of low priced
>>drugs for the developing world.
>>
>>Martin Foreman, director of the Panos Aids programme, warned that "[a]t
>>least 12 million people are in urgent need of treatment for AIDS. Only
>>if prices fall by at least 95% will antiretroviral drugs be accessible
>>to the majority who need them. Even then, families will have to make
>>tremendous
>>sacrifices."
>>
>>None of the major companies accepted Panos' invitation to speak at the
>>news conference.
>>
>>However, a Glaxo Wellcome spokesman told APM that the UN-led
>>international partnership against AIDS was the best way to expand
>>sustainable HIV/AIDS prevention, treatment and patient care
>>opportunities in developing countries.
>>
>>He said that the Brazilian generic producers only supplied about 20% of
>>the Brazilian market and therefore did not have spare capacity for
>>exports. In any case, he pointed out that the company's antiretrovirals
>>enjoy patent protection in most African countries.
>>
>>AIDS Treatment Data Network
>>611 Broadway, Suite #613
>>New York, NY 10012
>>Tel: (800) 734-7104
>>Fax: (212) 260-8869
>>E-mail: network@atdn.org
>>Internet: aidsinfonyc.org/network
>>
>>
>>
>>
>>
>>--__--__--
>>
>>_______________________________________________
>>Pharm-policy mailing list
>>Pharm-policy@lists.essential.org
>>http://lists.essential.org/mailman/listinfo/pharm-policy
>>
>>
>>End of Pharm-policy Digest
>>
>
>
>
>
>_______________________________________________
>Pharm-policy mailing list
>Pharm-policy@lists.essential.org
>http://lists.essential.org/mailman/listinfo/pharm-policy
>